Screening for factor V. Leiden mutation in users ofcombinedoral contraceptives or hormone replacement therapy
Authors:
D. Cibula 1; V. Unzeitig 2; J. Živný 1
Authors‘ workplace:
Gynekologicko-porodnická klinika 1. LF UK a VFN, Iřaha, přednosta prof. MUDr. J. Živný, DrSc. Gynekologicko-porodnická klinika LF MU a FN, Brno přednosta prof. MUDr. P Ventruba, DrSc
Published in:
Prakt. Lék. 2004; (7): 0
Category:
Overview
Objective:
Andysis of the issue of screening for Factor V Leiden mutation (FVL) in users ofcombined ord contraceptives (COC) or hormone replacement therapy (HRT).Design: Review article.Methods: Review of published facts, andysis of possibilities to screen dl users or to test riskgroups in the current situation in the Czech RepublicConclusion: 1. Screening for FVL in dl COC or HRT users is not recommended mostly for economicd ressons. 2. Testing for FVL is indicated in women with apositive fanily history of thromboembolic disease and in obese women, if they consider COC or HRT despite our recommendation or in čase there is a medicd indication. 3. Deep venous thrombosis or pulmonary embolism are absolute contrándications of COC or HRT regardless of the presence ofFVL.
Key words:
combined ord contraceptives, hormone replacement therapy, thromboembolic disease, Factor V Leiden mutation, hereditary thrombophilias
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2004 Issue 7
Most read in this issue
- Paroxetine in the treatment ofanxiety disorders
- Screening for factor V. Leiden mutation in users ofcombinedoral contraceptives or hormone replacement therapy
- An examination ofabortion laws in the Czech Republic and in the globál context
- Headache - options oftreatment